Portugal
Menu

SARS-CoV-2 Antigen Rapid Test Kits For Self Testing

COVID-19 Overview

Coronavirus disease 2019 (COVID-19) is of zoonotic origin and caused by the novel beta coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). People are generally susceptible. Currently, the patients infected by the novel coronavirus are the main source of infection; asymptomatic infected people can also be an infectious source. Based on the current epidemiological investigation, the incubation period is 1 to 14 days, mostly 3 to 7 days. The main manifestations include fever, fatigue and dry cough. Nasal congestion, runny nose, sore throat, myalgia and diarrhea are found in a few cases.

Antigen is generally detectable in upper respiratory specimens during the acute phase of infection. Rapid diagnosis of SARS-CoV-2 infection will help healthcare professionals to treat patients and control the disease more efficiently and effectively.

Product Information

The product is a rapid, lateral flow immumoassay intended for the qualitative detection of SARS-CoV-2 nucleocapsid antigen form anterior nasal swabs that are self-collected by an aindividual aged 18 years or older or are collected by an adult from an individual younger than 18 years old. This test is intended for use in individuals with symptoms or other epidemiological reasons to supect a COVID-19 infection.

Ordering Information

Catalog Number Description Format Size
56329 SARS-CoV-2 Antigen Rapid Test for Self Testing Cassette 5 tests

Benefits

• Non-invasive
• Simple to use
• No prescription needed
• Rapid, get result in 15 minutes
• Stable, with high accuracy
• Inexpensive, cost-efficiency

Specification

Time to result 15 minutes
Storage 2-30°C
Shelll life 24 months
Specimen type Nasal swab

Performance Characteristics

The Clinical performance study for SARS-CoV-2 Antigen Rapid Test Kit was conducted in Germany.

The positive and negative samples were all confirmed by PCR. The diagnostic sensitivity and diagnostic specificity of the product was 95,9% (90.8-98.2%) and 100% (96.3-100.0%) respectively.